Alira Health presents: A Novel hs-cTn Technology at ACC
Health Economics of measuring High-sensitive Cardiac Troponin at different Cut-offs in Non ST Segment Elevation Myocardial Infarction Patients with-in 6 Hours from Emergency Room Presentation
Giacomo Basadonna MD, PhD, Managing Director Global Medical Affairs, will present Alira Health’s proprietary, cost-effective, high sensitive troponin (hs-cTn) diagnostic technology at ACC.17, Washington, DC, U.S.A.
High-sensitive troponin (hs-ctn) can accurately rule-out acute myocardial infarction (AMI) at early hours with high negative predictive value (NPV). However, low positive predictive value (PPV) causes false positives, leaving many patients under observation (46.9%-54%). Our novel technology demonstrates that a diagnostic algorithm of hs-ctn measured at two different clinically accepted cut-offs within the first 6 hours after emergency room presentation can accurately diagnose 99.3% of non-st segment elevation myocardial infarction (NSTEMI) patients and is highly cost-effective.
Our approach has the potential to
- Increase the recognition of the hs-cTn in the U.S., especially at point of care
- Increase the acceptance of the hs-cTn among clinicians in the U.S. by addressing the diagnostic uncertainty of early rule out algorithms
Dr. Basadonna is a dynamic speaker who will walk you through his research and discovery and answer your questions on how this novel technology can improve patient care and cut costs.